Burning Rock Ltd (NASDAQ: BNR), a China-based medical technology company, has announced another partnership in the field of tumor companion diagnostics (CDx), this time with the German multinational corporation, Bayer. Previously Burning Rock had collaborated with Germany-based Merck KGaA in late 2021 for the development of CDx to support Merck’s MET inhibitor Tepmetko (tepotinib).
The new collaboration with Bayer will concentrate on the development of CDx products in China, aiming to bolster Bayer’s precision oncology portfolio through next-generation sequencing capabilities.- Flcube.com
